Development
Taysha Gene Therapies, Inc.
TSHA
$2.84
-$0.04-1.39%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -117.09M | -24.60M | -17.62M | -55.72M | -26.53M |
| Total Depreciation and Amortization | 331.00K | 343.00K | 331.00K | 364.00K | 277.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 106.18M | 6.28M | 2.10M | 42.13M | 5.08M |
| Change in Net Operating Assets | -7.37M | -796.00K | -5.00M | 27.51M | -7.64M |
| Cash from Operations | -17.95M | -18.77M | -20.19M | 14.28M | -28.81M |
| Capital Expenditure | 0.00 | 48.00K | -3.90M | -2.31M | -2.02M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.49M | -- | -- | -61.00K | -1.00M |
| Cash from Investing | -3.49M | 48.00K | -3.90M | -2.37M | -3.02M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 140.73M | 500.00K | 50.00K | 41.60M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -68.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -97.00K | -123.00K | -420.00K | 63.00K | -35.00K |
| Cash from Financing | 140.63M | 377.00K | -370.00K | 41.67M | -103.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 119.20M | -18.34M | -24.46M | 53.57M | -31.93M |